pdufa
.bio
Calendar
Decisions
Research
Home
›
Decisions
› NVCR 2026-02-12
NVCR
FDA decision
— Feb 12, 2026
✓ APPROVED
NovoCure Limited — Optune Pax · Locally advanced pancreatic cancer.
Run-up into the decision (T-120 → T+5)
PDUFA 2/12/26
$14.87
$10.03
8/28/25
Daily close, T-120 (8/28/25) through T+5. Run-up high $14.87 on 1/9/26, low $10.03 on 2/9/26 (T-120 to T-1). FDA decision 2/12/26. Historical price action, not a forecast.
Key facts
FDA decision date
2026-02-12
Outcome
Approved
Drug / candidate
Optune Pax
Company
NovoCure Limited
120-day run-up (T-120→T-1)
-11.8%
Not affiliated with or endorsed by the FDA.
Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio